title: Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
abstract: Treatment with ipilimumab, a monoclonal antibody that antagonizes cytotoxic T-lymphocyte antigen-4 (CTLA-4), results in improved survival of patients with stage IIIc-IV melanoma. However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. To evaluate the efficacy of ipilimumab for the treatment of brain metastasis in melanoma, a multicentre, retrospective analysis of 38 patients with brain metastases in melanoma, treated with ipilimumab in the context of the French Expanded Access Program, was performed. Three patients had a 3 partial response, 5 stable disease, 15 disease progression and 15 patients died during the induction phase due to disease progression. Median overall survival was 101 days (range 54-154). The brain metastases control rate was 16% (6/38). Ipilimumab may be effective in a few patients with central nervous system metastasis. However, patients with brain metastases and a low life expectancy may not benefit sufficiently from treatment with ipilimumab.
authors.affiliation: Department of Dermatology, Toulouse III University and Larrey Hospital, 31059 Toulouse Cedex 9, France.
authors.forename: Maria-Polina
authors.initials: MP
authors.lastname: Konstantinou
authors.forename: Caroline
authors.initials: C
authors.lastname: Dutriaux
authors.forename: Caroline
authors.initials: C
authors.lastname: Gaudy-Marqueste
authors.forename: Laurent
authors.initials: L
authors.lastname: Mortier
authors.forename: Christophe
authors.initials: C
authors.lastname: Bedane
authors.forename: Céline
authors.initials: C
authors.lastname: Girard
authors.forename: Sophie
authors.initials: S
authors.lastname: Thellier
authors.forename: Thomas
authors.initials: T
authors.lastname: Jouary
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Grob
authors.forename: Marie-Aleth
authors.initials: MA
authors.lastname: Richard
authors.forename: Caroline
authors.initials: C
authors.lastname: Templier
authors.forename: Lilia
authors.initials: L
authors.lastname: Sakji
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.forename: Carle
authors.initials: C
authors.lastname: Paul
authors.forename: Nicolas
authors.initials: N
authors.lastname: Meyer
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018450:Disease Progression; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D053208:Kaplan-Meier Estimate; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab